Optimal first-line treatment of chronic myeloid leukemia: How to use imatinib and what role for newer drugs?

Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalReview article

Abstract

The development of imatinib mesylate (Gleevec), a tyrosine kinase inhibitor targeted against the causative Bcr-Abl protein in chronic myeloid leukemia (CML), has resulted in hematologic and cytogenetic remissions in all phases of CML. Following imatinib treatment, more than 90% of patients obtain complete hematologic response, and 70% to 80% achieve a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging, exhibiting a major change in the natural history of the disease. The understanding of at least some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that may overcome this resistance. Combination strategies are currently being investigated in preliminary clinical studies and may prove to be useful. Overall, there are an increasing number of treatment options now available for patients with CML.

Original languageEnglish (US)
Pages (from-to)653-662
Number of pages10
JournalONCOLOGY
Volume21
Issue number6
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Pharmaceutical Preparations
Leukemia, Myeloid, Chronic Phase
Therapeutics
Protein-Tyrosine Kinases
Imatinib Mesylate
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Optimal first-line treatment of chronic myeloid leukemia : How to use imatinib and what role for newer drugs? / Jabbour, Elias; Cortes, Jorge; Kantarjian, Hagop.

In: ONCOLOGY, Vol. 21, No. 6, 01.05.2007, p. 653-662.

Research output: Contribution to journalReview article

@article{c0152afd47e648839e58d14d0dd2fe84,
title = "Optimal first-line treatment of chronic myeloid leukemia: How to use imatinib and what role for newer drugs?",
abstract = "The development of imatinib mesylate (Gleevec), a tyrosine kinase inhibitor targeted against the causative Bcr-Abl protein in chronic myeloid leukemia (CML), has resulted in hematologic and cytogenetic remissions in all phases of CML. Following imatinib treatment, more than 90{\%} of patients obtain complete hematologic response, and 70{\%} to 80{\%} achieve a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging, exhibiting a major change in the natural history of the disease. The understanding of at least some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that may overcome this resistance. Combination strategies are currently being investigated in preliminary clinical studies and may prove to be useful. Overall, there are an increasing number of treatment options now available for patients with CML.",
author = "Elias Jabbour and Jorge Cortes and Hagop Kantarjian",
year = "2007",
month = "5",
day = "1",
language = "English (US)",
volume = "21",
pages = "653--662",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "6",

}

TY - JOUR

T1 - Optimal first-line treatment of chronic myeloid leukemia

T2 - How to use imatinib and what role for newer drugs?

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2007/5/1

Y1 - 2007/5/1

N2 - The development of imatinib mesylate (Gleevec), a tyrosine kinase inhibitor targeted against the causative Bcr-Abl protein in chronic myeloid leukemia (CML), has resulted in hematologic and cytogenetic remissions in all phases of CML. Following imatinib treatment, more than 90% of patients obtain complete hematologic response, and 70% to 80% achieve a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging, exhibiting a major change in the natural history of the disease. The understanding of at least some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that may overcome this resistance. Combination strategies are currently being investigated in preliminary clinical studies and may prove to be useful. Overall, there are an increasing number of treatment options now available for patients with CML.

AB - The development of imatinib mesylate (Gleevec), a tyrosine kinase inhibitor targeted against the causative Bcr-Abl protein in chronic myeloid leukemia (CML), has resulted in hematologic and cytogenetic remissions in all phases of CML. Following imatinib treatment, more than 90% of patients obtain complete hematologic response, and 70% to 80% achieve a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging, exhibiting a major change in the natural history of the disease. The understanding of at least some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that may overcome this resistance. Combination strategies are currently being investigated in preliminary clinical studies and may prove to be useful. Overall, there are an increasing number of treatment options now available for patients with CML.

UR - http://www.scopus.com/inward/record.url?scp=34249940036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249940036&partnerID=8YFLogxK

M3 - Review article

C2 - 17564324

AN - SCOPUS:34249940036

VL - 21

SP - 653

EP - 662

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 6

ER -